Baseline Statin Use Appears to Protect Against Severe COVID-19
2024

Statins May Help Reduce Severe COVID-19 Outcomes

Sample size: 6905 Editorial Evidence: moderate

Author Information

Author(s): Eric A. Meyerowitz, Arthur Y. Kim

Primary Institution: Montefiore Medical Center

Hypothesis

Does baseline statin use reduce the risk of severe COVID-19 outcomes?

Conclusion

Baseline statin use appears to reduce the likelihood of severe COVID-19 outcomes, especially before widespread vaccination.

Supporting Evidence

  • Statin use was associated with a reduction in serious COVID-19 outcomes.
  • 84% of participants in both groups received COVID-19 vaccines by the end of the study.
  • The risk of serious COVID-19 was lower in the pitavastatin group compared to the placebo group.

Takeaway

Taking statins before getting COVID-19 might help you not get very sick from it, especially before vaccines were available.

Methodology

The study analyzed data from the REPRIEVE trial to examine the relationship between baseline statin use and COVID-19 outcomes.

Potential Biases

Potential confounding factors related to statin use may affect the results.

Limitations

The study did not meet the prespecified threshold for statistical significance due to a low number of severe events.

Participant Demographics

Participants were individuals with HIV, with 95% on treatment for over a year.

Statistical Information

P-Value

< .0001

Confidence Interval

95% CI, 0.52–1.03

Digital Object Identifier (DOI)

10.1093/ofid/ofae697

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication